title: Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
abstract: Glioblastoma multiforme (GBM) is characterized as one of the most common and most deadly malignant primary brain tumors. Current treatment modalities include the use of surgical resection and adjuvant chemotherapy and radiation therapy, though survival is still limited. Because of this, new treatment strategies are needed to improve overall survival. Immunotherapy has emerged as a potential treatment, but still possesses certain limitations to have a substantial clinical effect. In addition, nanotechnology has emerged as potent treatment effectors that have been shown to augment the effects of therapies including chemotherapy, gene therapy, and more. Nanoparticles possess a novel approach due to the myriad of functional groups that can create targeted treatments, though further optimization is still required. In this review, the authors will present the current uses and abilities of nanotechnology and its implication for use with immunotherapy in the treatment of GBM.
authors.affiliation: Department of Neurological Surgery, University of California Los Angeles, 300 Stein Plaza, St. 562, 5th Floor, Wasserman Bldg., Los Angeles, CA, 90095-6901, USA.
authors.forename: Nolan
authors.initials: N
authors.lastname: Ung
authors.forename: Isaac
authors.initials: I
authors.lastname: Yang
mesh_terms: D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D036103:Nanotechnology / Q000379:methods*